(Q37507973)

20 August 2017

1 reference

title

Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management (English)

1 reference

20 August 2017

1 reference

1 reference

1 reference

1 reference

2

Eduardo Tolosa

1 reference

20 August 2017

1

Angelo Antonini

1 reference

20 August 2017

language of work or name

1 reference

1 June 2009

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

20 August 2017

published in

1 reference

20 August 2017

volume

9

1 reference

20 August 2017

issue

6

1 reference

20 August 2017

page(s)

859-867

1 reference

Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system

20 August 2017

cites work

1 reference

Levodopa in the treatment of Parkinson's disease: a consensus meeting

21 January 2018

1 reference

Treatment interventions for Parkinson's disease: an evidence based assessment

21 January 2018

1 reference

The response to levodopa in Parkinson's disease: imposing pharmacological law and order

21 January 2018

1 reference

Levodopa-induced dyskinesias

21 January 2018

1 reference

Impact of the motor complications of Parkinson's disease on the quality of life

21 January 2018

1 reference

Non-motor symptoms in Parkinson's disease

21 January 2018

1 reference

The pathogenesis of cell death in Parkinson's disease--2007.

21 January 2018

1 reference

Molecular pathogenesis of Parkinson's disease

21 January 2018

1 reference

Levodopa prolongs life expectancy and is non-toxic to substantia nigra

21 January 2018

1 reference

Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA.

21 January 2018

1 reference

Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation

21 January 2018

1 reference

Molecular mechanisms underlying levodopa-induced dyskinesia.

21 January 2018

1 reference

Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease

21 January 2018

1 reference

Treatment of levodopa-induced motor complications

21 January 2018

1 reference

Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus).

21 January 2018

1 reference

L-dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations

21 January 2018

1 reference

Effect of pulsatile administration of levodopa on dyskinesia induction in drug‐naïve MPTP‐treated common marmosets: Effect of dose, frequency of administration, and brain exposure

21 January 2018

1 reference

Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates

21 January 2018

1 reference

Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment

21 January 2018

1 reference

Striatal glutamatergic mechanisms and extrapyramidal movement disorders

21 January 2018

1 reference

Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications

21 January 2018

1 reference

Parkinson's disease: levodopa-induced dyskinesia and signal transduction.

21 January 2018

1 reference

Nondopaminergic mechanisms in levodopa-induced dyskinesia

21 January 2018

1 reference

The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits.

21 January 2018

1 reference

Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications

21 January 2018

1 reference

Continuous dopaminergic stimulation in early and advanced Parkinson's disease

21 January 2018

1 reference

Deep brain stimulation and continuous dopaminergic stimulation in advanced Parkinson's disease

21 January 2018

1 reference

A 10 year retrospective audit of long-term apomorphine use in Parkinson's disease

21 January 2018

1 reference

Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges

21 January 2018

1 reference

Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observations

21 January 2018

1 reference

Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease

21 January 2018

1 reference

Intermittent subcutaneous apomorphine therapy for 'off' episodes in Parkinson's disease: a 6-month open-label study

21 January 2018

1 reference

Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus

21 January 2018

1 reference

Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease

21 January 2018

1 reference

Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years.

21 January 2018

1 reference

On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients

21 January 2018

1 reference

On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study.

21 January 2018

1 reference

Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease

21 January 2018

1 reference

Duodenal levodopa infusion for the treatment of Parkinson's disease

21 January 2018

1 reference

Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease

21 January 2018

1 reference

New strategies in motor parkinsonism

21 January 2018

1 reference

Continuous dopaminergic stimulation--from theory to clinical practice

21 January 2018

1 reference

Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease

21 January 2018

1 reference

Individualized assessment of quality of life in idiopathic Parkinson's disease.

21 January 2018

1 reference

Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome.

21 January 2018

1 reference

Duodenal levodopa infusion in Parkinson's disease--long-term experience

21 January 2018

1 reference

Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease

21 January 2018

1 reference

Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease.

21 January 2018

1 reference

Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease

21 January 2018

1 reference

Clinical and cerebral activity changes induced by subthalamic nucleus stimulation in advanced Parkinson's disease: a prospective case-control study.

21 January 2018

1 reference

Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

Deep brain stimulation: preoperative issues

21 January 2018

1 reference

Does ageing influence deep brain stimulation outcomes in Parkinson's disease?

21 January 2018

1 reference

Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial

21 January 2018

1 reference

Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study

21 January 2018

1 reference

Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up

21 January 2018

1 reference

Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERN.09.48

1 reference

20 August 2017

1 reference